|
Match
|
Document |
Document Title |
|
|
US20090286883 |
TREATMENT OF HEART FAILURE AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS
Administration of monoamine oxidase inhibitors is useful in the prevention and treatment of heart failure and incipient heart failure.
|
|
|
US20090281195 |
NOVEL COCRYSTALLIZATION
The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a...
|
|
|
US20090264470 |
CB1 Antagonists and Inverse Agonists
The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention. The present invention further relates to the...
|
|
|
US20090238869 |
PROPRANOLOL FORMULATIONS
Controlled-release propranolol formulations comprise a core comprising a pharmaceutically acceptable propranolol salt and an inert core; and a coating disposed on the core, the coating comprising...
|
|
|
US20090233941 |
Co-Crystals of Calixarenes and Biologically Active Molecules
This invention relates to co-crystals of at least one molecule of calyx[n]arene or at least one of its derivatives, and at least one biologically active molecule, compositions and medicines...
|
|
|
US20090227682 |
XETINE COMPOSITIONS
The invention provides a xetine or salt thereof composition having a dissolution in a phosphate buffer at pH 6.8, using USP basket 10 Mesh at 75 rpm, of at least 15% at 60 minutes, of at least 40%...
|
|
|
US20090221658 |
Pharmacological Treatment for Sleep Apnea
The present invention relates generally to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of agents or combinations of agents...
|
|
|
US20090215907 |
DOSING REGIMES FOR TRANS-CLOMIPHENE
The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with...
|
|
|
US20090215906 |
METHODS AND MATERIALS WITH TRANS-CLOMIPHENE FOR THE TREATMENT OF MALE INFERTILITY
Compositions comprising trans-clomiphene for treating male infertility may be used to treat male infertility.
|
|
|
US20090215738 |
PREVENTION AND TREATMENT OF AN INCREASE IN CARDIOVASCULAR RISK, ADVERSE CARDIOVASCULAR EVENTS, INFERTILITY, AND ADVERSE PSYCHOLOGICAL EFFECTS AFTER ANDROGEN OR GNRH ANALOGUE INTAKE
Disclosed is a is a treatment for the adverse psychological effects (including depression, low self esteem, guilt, increased stress, anhedonia, decreased cognition, sleep disturbances, general...
|
|
|
US20090215733 |
THERAPY FOR THE PROPHYLAXIS OR TREATMENT OF ADVERSE BODY COMPOSITION CHANGES AND/OR DECREASED MUSCLE STRENGTH AFTER ANDROGEN OR GNRH ANALOGUE INTAKE
Methods of treating or reducing the risk of one or more effects or signs of induced hypogonadism after androgen or GnRH intake are disclosed herein. In an embodiment, a method of treating one or...
|
|
|
US20090214643 |
IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES
Methods for administering beta-adrenergic inverse agonists with improved pharmacokinetic profiles for the treatment of pulmonary airway diseases are disclosed. The beta adrenergic inverse agonists...
|
|
|
US20090202572 |
COMPOSITIONS AND METHODS FOR MODULATING BONE MASS
The instant invention relates to compositions and methods for treating or preventing bone diseases. In certain aspects, the invention provides compositions comprising a β-adrenergic antagonist or...
|
|
|
US20090176878 |
GENETIC POLYMORPHISMS AND SUBSTANCE DEPENDENCE
The invention encompasses a method for identifying subjects at risk for substance dependence by detecting the presence of polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene....
|
|
|
US20090170857 |
Method for healing a wound using a direct vasodilator
A method for healing a wound comprising the step of topically administering a wound healing composition to a wounded area, wherein the wound healing composition comprises a first medicament...
|
|
|
US20090169604 |
Adhesive Pharmaceutical Preparation Containing Bisoprolol
In the adhesive pharmaceutical preparation of the invention containing bisoprolol, a pressure-sensitive adhesive layer is laminated on one side of the backing. The pressure-sensitive adhesive layer...
|
|
|
US20090155360 |
ORALLY DISINTEGRATING TABLETS COMPRISING DIPHENHYDRAMINE
The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in...
|
|
|
US20090105349 |
ANDROGEN MODULATORS
The present invention is directed to the discovery of a new class of androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease sebum...
|
|
|
US20090099265 |
TRANS-CLOMIPHENE FOR METABOLIC SYNDROME
The present invention relates to the administration of compositions comprising an antiestrogen, preferably trans-clomiphene, for treating metabolic syndrome in a subject. The invention is also...
|
|
|
US20090069440 |
DEUTERIUM-ENRICHED ATOMOXETINE
The present application describes deuterium-enriched atomoxetine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
US20090069267 |
CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous...
|
|
|
US20090068273 |
Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
The invention provides inhalation devices comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino
]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; or a salt or solvate...
|
|
|
US20090062353 |
Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and...
|
|
|
US20090053310 |
NOVEL SUSTAINED RELEASE DOSAGE FORM
The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer...
|
|
|
US20090036488 |
RECURRENCE PREVENTIVE THERAPEUTIC AGENT FOR PSYCHOSTIMULANT-INDUCED PSYCHOSIS AND SCHIZOPHRENIA
The present invention provides a therapeutic agent for preventing recurrence of psychostimulant-induced psychosis and schizophrenia. This therapeutic agent for preventing recurrence of...
|
|
|
US20090030084 |
Compositions and Methods of Use of Electron Transport System Inhibitors
The invention provides compounds of the formula: or a pharmaceutically acceptable salt thereof, where m, n, R 1 , R 2 , R 3 R 4 , R 5 , R 6 , R 7 are those defined herein. The invention also...
|
|
|
US20090029922 |
Use of S1P receptor agonists in heart diseases
The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.
|
|
|
US20090029901 |
Process for Crystallizing Lactose Particles for Use in Pharmaceutical Formulations
A process for producing a plurality of lactose particles comprises subjecting a plurality of lactose particles, to conditions such that at least a portion of smaller lactose particles detach from...
|
|
|
US20090023751 |
COMPOUNDS THAT PROTECT AGAINST SENSORY HAIR CELL DEATH
The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds...
|
|
|
US20090023705 |
DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS OR ATTENTION DEFICIT DISORDERS
The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood...
|
|
|
US20080319086 |
DEUTERIUM-ENRICHED SALMETEROL
The present application describes deuterium-enriched salmeterol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
US20080318880 |
Neoadjuvant treatment of Breast Cancer
Neoadjuvant treatment of inflammatory or T3 to T4 breast cancer is carried out by administering to such patients a number of cycles of chemotherapy treatment in which DPPE first is administered...
|
|
|
US20080311099 |
Pyridoxal-5-Phosphate and Related Compounds in Combination With Therapeutic Cardiovascular Compounds for Treating Angina
Methods for treating angina are described. A method for treating angina includes concurrently administering a compound with a therapeutic cardiovascular compound. A combination therapy employs...
|
|
|
US20080306035 |
Methods and Compositions for Treating Female Infertility Using Clomiphene
The present invention relates to the use of compositions comprising clomiphene for treating female infertility. The invention is also directed to a regimen of treatment for female infertility using...
|
|
|
US20080300164 |
Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making
A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity,...
|
|
|
US20080293735 |
Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of...
|
|
|
US20080269346 |
B-Blocker Pharmacogenetics in Heart Failure
Polymorphisms in the beta-1 adrenergic receptor that (1) affect tolerability to beta-blocker treatment or (2) influence responsiveness to beta-blocker treatment are disclosed. Additionally, methods...
|
|
|
US20080255074 |
Drug Combination Comprising A Selective Serotonin Reuptake Inhibitor And A Glucocorticoid Receptor Antagonist For The Treatment Of Depression
The invention provides for a combination comprising an amount of an SSRI, or a pharmaceutically acceptable salt or solvate thereof, and an amount of a GR antagonist, or a pharmaceutically...
|
|
|
US20080253960 |
Lipoprotein-Based Nanoplatforms
The present invention provides a non-naturally occurring lipoprotein nanoplatform (“LBNP”) comprising at least one cell surface receptor ligand; at least one lipoprotein; and at least one...
|
|
|
US20080220080 |
Multiparticulate Pharmaceutical form Comprising Pellets with a Substance Having a Modular Effect in Relation to Active Ingredient Release
The invention relates to a multiparticulate pharmaceutical form, comprising pellets with a multilayer structure for controlled active ingredient release, comprising a) a core layer comprising a...
|
|
|
US20080200555 |
USE OF NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF TIC DISORDERS
Selective norepinephrine reuptake inhibitors are used to treat tic disorders.
|
|
|
US20080193464 |
Human Autism Susceptibility Gene Encoding Prkcb1 and Uses Thereof
The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as...
|
|
|
US20080188557 |
Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof
The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful...
|
|
|
US20080182898 |
Treatment of metabolic syndrome with norfluoxetine
The invention relates to methods of treating metabolic syndrome, or the specific disorders associated with metabolic syndrome, comprising the administration of norfluoxetine enriched for the (R) or...
|
|
|
US20080176793 |
UPREGULATING ACTIVITY OR EXPRESSION OF BDNF TO MITIGATE COGNITIVE IMPAIRMENT IN ASYMPTOMATIC HUNTINGTON'S SUBJECTS
This invention provides novel methods of treatment to ameliorate or prevent cognitive disorder/dysfunction in pre- or asymptomatic subject having one or more mutations in the Huntington gene. The...
|
|
|
US20080153832 |
PAN-ALPHA-2 RECEPTOR AGONIST AND RELAXANT COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS
Disclosed herein is a pharmaceutical composition comprising a relaxant and a pan-alpha-2 receptor agonist. The composition is effective for treating gastrointestinal motility disorders, and methods...
|
|
|
US20080153830 |
ALPHA AND/OR BETA-ADRENERGIC ANTAGONISTS AND AGONISTS TO TREAT PAIN
The present disclosure provides for improved methods for treating pain, including pain associated with chronic inflammatory diseases, neuropathic pain and cancer by using α-adrenergic antagonists...
|
|
|
US20080146675 |
Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
Stable Atomoxetine hydrochloride, a process for the manufacture thereof, the use of stable Atomoxetine Hydrochloride for making a pharmaceutical formulation, a process for the preparation of any...
|
|
|
US20080145318 |
ATOMOXETINE FORMULATIONS AND ASSOCIATED METHODS
Methods and formulations for delivering atomoxetine compounds that minimize drug metabolism and thus increase the effectiveness of the drug are disclosed. The in vivo potency of the atomoxetine...
|
|
|
US20080140450 |
Treatment of metabolic syndrome with norfluoxetine
The invention relates to methods of treating metabolic syndrome, or the specific disorders associated with metabolic syndrome, comprising the administration of norfluoxetine enriched for the (R) or...
|